| 0 (0%) | 03-09 22:09 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.91 |
1-year : | 38.2 |
| Resists | First : | 32.46 |
Second : | 32.7 |
| Pivot price | 32.49  |
|||
| Supports | First : | 32.06 |
Second : | 26.68 |
| MAs | MA(5) : | 32.5 |
MA(20) : | 32.45 |
| MA(100) : | 31.88 |
MA(250) : | 30.37 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.5 |
D(3) : | 67.9 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 32.7 | Low : | 25.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MRCP ] has closed above bottom band by 0.3%. Bollinger Bands are 7.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.57 - 32.73 | 32.73 - 32.87 |
| Low: | 31.98 - 32.16 | 32.16 - 32.31 |
| Close: | 32.25 - 32.52 | 32.52 - 32.75 |
Thu, 05 Mar 2026
Tips for passing the MRCP Part One - The BMJ
Sun, 15 Feb 2026
Understanding MRCP Test: Benefits and Risks Explained - Health: Trusted and Empathetic Health and Wellness Information
Wed, 21 Jan 2026
Stephen Lam Chan, MD, FRCP, MRCP, on HCC: Pembrolizumab After Resection or Local Ablation - The ASCO Post
Fri, 16 Jan 2026
The application of a three-dimensional gradient spin‒echo sequence (GRASE) in magnetic resonance cholangiopancreatography - Nature
Sun, 04 Jan 2026
A Rare and Aggressive Klatskin Tumor Revealed by Magnetic Resonance Cholangiopancreatography (MRCP): A Diagnostic Case Report - Cureus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|